News

Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro to form a new strategic commercial alliance aimed at delivering improvements to the global availability of RNA-based health treatments and address a crucial skills gap in the industry. The new alliance combines Ardena’s expertise in custom development and […]

We are pleased to announce a major achievement in the development of our new Nanomedicines facility in Oss, Netherlands. Our team celebrated a significant milestone in the construction process yesterday by marking the highest point of the building. We were delighted to share this special moment with our esteemed partners and local authorities. As we […]

Ardena and Sciex have recently collaborated on the development of a sensitive assay for the bioanalysis of glycosphingolipids in human cerebrospinal fluid. Would you like to learn more about this assay or other lipid assays or to explore the possibilities for your research program together with us, please check the technical note or visit our […]

Our customer Vicore Pharma Holding AB has recently announced the initiation of a first-in-human trial with C106, an orally available novel drug with target engagement and anti-fibrotic effects in human fibrotic lung and kidney tissue at clinically relevant concentrations. At Ardena, we sincerely congratulate Vicore’s team on this important milestone. We are proud of our […]

Ardena acquires Idifarma from Suanfarma, adding spray drying technology and high potency capabilities Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO), announced today that it has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs. The acquisition from Suanfarma delivers expansion across Southern Europe and supports Ardena’s […]